A humanized, Fc-engineered anti-LILRB1 IgG antibody, B1-176, with reduced FcγR binding was shown to disrupt LILRB1 signaling in co-culture experiments with LILRB1 reporter cells and various tumor cell lines (92). This evidence concerns the gene FCGR2A and neoplasm.